Literature DB >> 22800301

The positional specificity of EXXK motifs within an amphipathic α-helix dictates preferential lysine modification by acrolein: implications for the design of high-density lipoprotein mimetic peptides.

Ying Zheng1, Sea H Kim, Arti B Patel, Vasanthy Narayanaswami, Anthony T Iavarone, Gregory L Hura, John K Bielicki.   

Abstract

Despite the ability of acrolein to damage proteins, factors governing its reactivity with the ε-amino group of lysine are poorly understood. We used a small 26-mer α-helical peptide (ATI-5261) to evaluate the influence of acidic glutamate (E) residues on site-specific lysine modification by acrolein and if this targeting played a major role in inhibiting the cholesterol efflux activity of the peptide. Exposure of ATI-5261 to acrolein resulted in N-(3-formyl-3,4-dehydropiperidino) (FDP)-lysine adducts at positions 5 and 25 and led to a concentration-dependent reduction in cholesterol efflux activity (55 ± 7 and 83 ± 3% decrease with 5:1 and 20:1 acrolein:peptide molar ratios, respectively). Amino acid substitution (K → R) experiments and mass spectrometry revealed neither K5 nor K25 was preferentially modified by acrolein, despite the location of K5 within a putative EXXK motif. Moreover, both lysine residues remained equally reactive when the lipidated peptide was exposed to acrolein. In contrast, placement of EXXK in the center of ATI-5261 resulted in site-specific modification of lysine. The latter was dependent on glutamate, thus establishing that acidic residues facilitate lysine modification and form the molecular basis of the EXXK motif. Preferential targeting of lysine, however, failed to augment the inhibitory effect of the aldehyde. Overall, the inhibitory effects of acrolein on cholesterol efflux activity were largely dependent on the number of lysine residue modifications and cross-linking of α-helical strands that restricted dissociation of the peptide to active forms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22800301     DOI: 10.1021/bi300626g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry.

Authors:  Tuyen N Tran; Malathi G Kosaraju; Shiori Tamamizu-Kato; Olayemi Akintunde; Ying Zheng; John K Bielicki; Kent Pinkerton; Koji Uchida; Yuan Yu Lee; Vasanthy Narayanaswami
Journal:  Biochemistry       Date:  2014-01-08       Impact factor: 3.162

2.  Mechanisms Underlying Acrolein-Mediated Inhibition of Chromatin Assembly.

Authors:  Lei Fang; Danqi Chen; Clinton Yu; Hongjie Li; Jason Brocato; Lan Huang; Chunyuan Jin
Journal:  Mol Cell Biol       Date:  2016-11-14       Impact factor: 4.272

Review 3.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

Review 4.  Apolipoprotein A-I mimetics.

Authors:  Srinivasa T Reddy; Mohamad Navab; Gattadahalli M Anantharamaiah; Alan M Fogelman
Journal:  Curr Opin Lipidol       Date:  2014-08       Impact factor: 4.776

5.  Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship.

Authors:  Mark T Lek; Siobanth Cruz; Nnejiuwa U Ibe; Wendy H J Beck; John K Bielicki; Paul M M Weers; Vasanthy Narayanaswami
Journal:  PLoS One       Date:  2017-06-23       Impact factor: 3.240

Review 6.  Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents.

Authors:  Skylar T Chuang; Siobanth Cruz; Vasanthy Narayanaswami
Journal:  Nanomaterials (Basel)       Date:  2020-05-08       Impact factor: 5.076

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.